GlaxoSmithKline PLC has now put into place the third prong of its strategy to become a leader in the bioelectric medicine and technology space with the inception of a $50 million venture capital fund that will give a “jump start” to entrepreneurs in the field.
The fund, dubbed Action Potential Venture Capital, has a clear mission to invest in five to seven start-ups that are making progress in the field of bioelectrical medicine. Like other...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?